Yield10 Bioscience, 21 Erie St, Cambridge, MA 02139, US

Gritstone Oncology is a biotechnology company based in Cambridge, MA, that is dedicated to developing innovative immunotherapies for cancer and infectious diseases. Their approach involves harnessing the power of the patient's immune system to recognize and destroy tumors or virally infected cells, with a focus on T cell recognition and proliferation. Through their proprietary platforms, Gritstone has developed a portfolio of immunotherapies designed to activate and direct the immune system, offering new opportunities for more patients to benefit from immunotherapy. With a strong emphasis on personalized medicine, Gritstone is developing individualized cancer vaccines, known as GRANITE, that target neoantigens specific to each patient. They are also working on off-the-shelf immunotherapies, known as SLATE, which utilize shared neoantigens derived from driver mutations. In addition to their cancer vaccine programs, Gritstone is leveraging their core technologies to develop next-generation vaccines for infectious diseases, including a collaboration with Gilead Sciences to research and develop a vaccine-based immunotherapy for HIV infection. Their facilities in Pleasanton, CA, Emeryville, CA, and Cambridge, MA, house their manufacturing capabilities, research labs, and development teams.Generated from the website

BioMed Realty

Tvisions

Metabolix

Prime Medicine, Inc